ABX464, a once-daily, oral treatment for ulcerative colitis, showed efficacy for up to 2 years of therapy in a phase 2a trial, according to the drug’s manufacturer Abivax.
In the study, researchers randomly assigned patients with UC who were refractory or intolerant to at least one existing treatment to receive either ABX464 or placebo in an initial induction phase. For the maintenance phase, they enrolled 22 patients in the 50 mg once-daily open label study.
At 52 weeks, 19 patients remained on treatment, and 16 of those patients completed 2 years of therapy.
Researchers found that 69% of